12.1 Practice Guidelines and Drug Information
Key Takeaways
- Evidence-based practice (EBP) integrates the best research evidence, clinical expertise, and patient values — no single element alone defines optimal care.
- Major US guideline bodies tested on the FPGEE include ADA (diabetes), AHA/ACC (cardiovascular), GOLD (COPD), GINA (asthma), IDSA (infectious diseases), KDIGO (kidney), NCCN (oncology), and USPSTF (preventive services).
- The AGREE II tool appraises guideline quality across six domains including scope, stakeholder involvement, rigor, clarity, applicability, and editorial independence.
- The drug information hierarchy moves from tertiary sources (textbooks, AHFS, Lexicomp, Micromedex, UpToDate) to secondary indexing services to primary literature (RCTs, cohort studies, case reports).
- A systematic drug information response uses PICO/PICOT to frame an answerable question, then searches PubMed/MEDLINE, Embase, and Cochrane with MeSH terms and Boolean operators before synthesizing and responding.
12.1 Practice Guidelines and Drug Information
Quick Answer: Evidence-based practice (EBP) integrates the best research evidence, clinical expertise, and patient values. The FPGEE expects you to know the major US guideline bodies — ADA, AHA/ACC, GOLD, GINA, IDSA, KDIGO, NCCN, USPSTF — and to appraise guidelines with the AGREE II tool. Drug information skills follow a systematic path: frame a PICO/PICOT question, search PubMed/MEDLINE, Embase, Cochrane with MeSH terms and Boolean operators, and weigh tertiary → secondary → primary sources.
Defining Evidence-Based Practice
Evidence-based practice (EBP), formalized by Sackett and colleagues, is the conscientious, explicit, and judicious use of current best evidence in making decisions about individual patients. It integrates three components: (1) the best research evidence from clinically relevant studies, (2) clinical expertise (the practitioner's accumulated experience and judgment), and (3) patient values (the individual's preferences, concerns, and expectations). Neglect any one element and care suffers — research without patient values becomes paternalism; patient values without evidence becomes quackery; expertise without evidence becomes dogma.
Major US Clinical Practice Guidelines
The FPGEE tests working knowledge of the most influential guideline bodies and their actionable recommendations.
| Guideline Body | Scope | Key FPGEE-Relevant Recommendations |
|---|---|---|
| ADA (American Diabetes Association) Standards of Care | Diabetes mellitus | HbA1c target < 7% for most; metformin first-line for type 2; add SGLT2 inhibitor or GLP-1 receptor agonist in ASCVD, heart failure, or CKD; insulin initiation when oral agents fail |
| AHA/ACC (American Heart Association / American College of Cardiology) | Cardiovascular disease | Hypertension target < 130/80 mmHg; statin intensity matched to ASCVD risk; heart failure GDMT = ARNI (or ACEI/ARB), beta-blocker, MRA, SGLT2i; atrial fibrillation prefers DOACs over warfarin in most patients |
| GOLD (Global Initiative for Chronic Obstructive Lung Disease) | COPD | LAMA/LABA for GOLD Group C/D; ICS added only when eosinophils ≥ 300 or exacerbation history warrants; stepwise escalation by symptoms and exacerbation risk |
| GINA (Global Initiative for Asthma) | Asthma | Stepwise treatment; SMART therapy (single inhaler ICS-formoterol as both maintenance and rescue) is preferred in adolescents and adults at Step 3–4 |
| IDSA (Infectious Diseases Society of America) | Infectious diseases | CAP, UTI, SSTI, sepsis, and C. difficile pathways; prefer narrowest-spectrum effective agent; stewardship-driven |
| KDIGO (Kidney Disease: Improving Global Outcomes) | Kidney disease | CKD staging by GFR and albuminuria; BP target < 120/80 (systolic) in albuminuric CKD; anemia managed with iron and ESA when Hb < 10 g/dL |
| NCCN (National Comprehensive Cancer Network) | Oncology | Tumor-specific regimens updated continuously; category 1 versus 2A/2B evidence ratings |
| USPSTF (US Preventive Services Task Force) | Preventive services | Grade A and B recommendations (e.g., statins for 40–75 year olds at ≥ 10% ASCVD risk; colorectal screening 45–75); ACA requires coverage of A/B services without cost-sharing |
Appraising Guidelines: AGREE II
Not every guideline is trustworthy. The AGREE II instrument (Appraisal of Guidelines for Research and Evaluation) scores a guideline across six domains: (1) scope and purpose, (2) stakeholder involvement, (3) rigor of development (most heavily weighted — evidence synthesis, recommendation grading), (4) clarity and presentation, (5) applicability (implementation facilitators and barriers), and (6) editorial independence (conflicts of interest, funding source). Each domain is scored 1–7; the rigor and independence domains are the most discriminating. Before applying a guideline, also verify currency (publication and update dates), scope fit to your patient, and author conflicts of interest.
Applying Guidelines to Individual Patients
Guidelines describe what to do for a typical patient; they are not mandates. Real patients have comorbidities, contraindications, and preferences that push therapy off the recommended path. A guideline that recommends a DOAC for stroke prevention in AFib must be flexed when the patient has severe renal impairment or cannot afford the copay. The FPGEE tests this judgment — recognize the guideline-preferred option, but identify the patient-specific reason it may not apply.
Drug Information Skills
Pharmacists are the drug information (DI) specialists of the health care team. A rigorous response follows a systematic approach: (1) refine the question, (2) conduct a literature search, (3) evaluate the evidence, (4) synthesize findings, and (5) formulate and deliver the response.
Framing an Answerable Question: PICO and PICOT
A vague request like "Is drug X safe in pregnancy?" cannot be searched efficiently. The PICO framework structures it: Population (pregnant women with hypertension), Intervention (labetalol), Comparator (methyldopa), Outcome (fetal safety, BP control). Adding Time and Setting extends to PICOTS, useful for systematic reviews and guideline questions.
Search Strategies
The core databases are PubMed/MEDLINE (US biomedical literature), Embase (European, stronger drug and conference content), and the Cochrane Library (systematic reviews and CENTRAL trial register). MeSH (Medical Subject Headings) terms index articles by controlled vocabulary — "Metformin"[MeSH] AND "Type 2 Diabetes Mellitus"[MeSH] — and combine with Boolean operators (AND, OR, NOT) and field tags (ti, ab, tw, pt). Use AND to narrow, OR to expand synonyms, and NOT sparingly to avoid losing relevant hits. Filters (randomized controlled trial, humans, last 5 years) further refine results.
Hierarchy of Information Sources
Drug information sources fall into three tiers:
- Tertiary sources synthesize primary literature into convenient references. Examples include textbooks (DiPiro's Pharmacotherapy, Koda-Kimble & Young's Applied Therapeutics), drug compendia (AHFS Drug Information, Drug Information Handbook), and online databases (Lexicomp, Micromedex, UpToDate, Clinical Pharmacology). Use tertiary sources for background, dosing, interactions, and stable clinical questions; recognize they lag 1–3 years behind primary literature.
- Secondary sources are indexing and abstracting services (PubMed/MEDLINE, Embase, Scopus, IPA/International Pharmaceutical Abstracts) that point you to primary literature.
- Primary sources are the original studies themselves — RCTs, cohort studies, case-control studies, case reports, case series. Use primary sources for new or controversial questions where tertiary sources are silent or out of date.
Formulary Management, Off-Label Use, and Shortages
The Pharmacy and Therapeutics (P&T) Committee manages the formulary through drug monographs (single-agent evaluations), class reviews (therapeutic alternatives compared head-to-head), and new-product evaluations. Decisions weigh efficacy, safety, cost, and place in therapy. Off-label use evaluation requires evidence of demonstrated benefit, absence of approved alternatives, and supportive guideline or compendia citation (note the ACCC v. Cuomo legal backdrop permitting truthful off-label promotion in the US). Drug shortage management follows ASPE and FDA guidance: identify the affected product and estimated duration, notify prescribers and patients, select therapeutic alternatives by efficacy and safety equivalence, adjust dosing for organ function, and document the rationale.
Putting It Together
A pharmacist asked whether a 68-year-old patient with type 2 diabetes, HFpEF, and CKD stage 3b should be on a particular agent would: consult ADA Standards of Care and KDIGO (tertiary synthesis), confirm the trial evidence base (EMPA-REG OUTCOME, CANVAS) via PubMed (primary), and weigh patient-specific factors (eGFR, cost, preferences). That sequence — guideline anchored in primary evidence, filtered through expertise and values — is evidence-based practice in action.
A pharmacist is asked whether a 72-year-old patient with type 2 diabetes, established ASCVD, and CKD stage 3 should add a specific agent to metformin. Which guideline bodies are the most authoritative primary references to consult first?
Which statement about the AGREE II instrument is correct?
A requestor asks, "Is drug X safe in pregnancy?" Before searching PubMed, the pharmacist reformulates the question as: "In pregnant women with hypertension, is labetalol compared with methyldopa?" Which PICO element is missing?